Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Peripheral Mobilized Mononuclear Cell-based Therapy in Diabetic Painful Neuropathy
NCT02315235Withdrawn
- Sponsor
- Seoul National University Hospital
- Start
- May 2014
- Primary completion
- Mar 2016
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Randomised, single-blind trial of autologous G-CSF mobilized peripheral blood mononuclear cells in diabetic neuropathy (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Changes in pain for a week after the procedure at 12 weeks. Planned start May 2014; status: withdrawn.
02
Drugs
autologous G-CSF mobilized peripheral blood mononuclear cells
03
Conditions
diabetic neuropathy
Beyond the preview
Go deeper on NCT02315235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315235.